In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, WELL Health Technologies Corp (WELL – Research Report). Analyst Justin Keywood from Stifel Nicolaus remains bullish on the stock.
According to TipRanks.com, Keywood is a 3-star analyst with an average return of 1.1% and a 42.5% success rate. Keywood covers the Healthcare sector, focusing on stocks such as Andlauer Healthcare Group, Cipher Pharmaceuticals, and Knight Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for WELL Health Technologies Corp with a C$8.44 average price target, which is a 78.4% upside from current levels. In a report issued on July 13, Haywood also maintained a Buy rating on the stock with a $8.00 price target.
WELL Health Technologies Corp’s market cap is currently C$1.08B and has a P/E ratio of -246.28.
WELL Health Technologies Corp is the owner and operator of a portfolio of Primary Hclinics delivering healthcare-related services It operates through below segments: Clinical services, Digital services, and others. It also engages in the Electronic Medical Records business that supports the digitization of clinics. Its objective is to empower doctors to provide the best and most advanced care possible leveraging the latest trends in digital health.
The company’s shares closed last Thursday at C$4.76.
Read More on TSE:WELL:
